Galmed Pharmaceuticals Ltd.
GLMDNASDAQHealthcare● Active
$0.47
$-0.23(-32.57%)
Market Cap$2571403
P/E Ratio—
52W High$2.34
52W Low$0.411
Galmed Pharmaceuticals Ltd. (GLMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GLMD · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 31, 2026EPS Actual
-$0.92
Est. -$0.38 · -142.1%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 31, 2026
After Market Close
▼ Miss EPS
GLMD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.39 | — | — | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.38 | -$0.92 | -142.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.51 | -$0.80 | -56.9% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 26, 2025 | -$0.54 | -$0.33 | +38.9% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 28, 2025 | -$0.83 | $0.63 | +175.9% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 22, 2025 | -$0.89 | -$0.62 | +30.3% | $0.00B | $0.00B | +0.0% |
| — Q2 FY2025 | Apr 2, 2025 | — | -$11.76 | — | $0.00B | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$2.31 | — | — | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.92
EPS Est.
-$0.38
EPS Surpr.
-142.1%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.80
EPS Est.
-$0.51
EPS Surpr.
-56.9%
Revenue
—
Q4 FY2025
Nov 26, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.54
EPS Surpr.
+38.9%
Revenue
—
Q3 FY2025
Aug 28, 2025Beat
EPS Actual
$0.63
EPS Est.
-$0.83
EPS Surpr.
+175.9%
Revenue
—
Q2 FY2025
May 22, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.89
EPS Surpr.
+30.3%
Revenue
$0.00B
Q2 FY2025
Apr 2, 2025
EPS Actual
-$11.76
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$2.31
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q3 FY2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q2 FY2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q1 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2025 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2025 | $-0.54 | $-0.54 | $-0.54 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 31, 2026 | -142.1% | $0.47 | $0.49 | +3.17% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -56.9% | $0.47 | $0.49 | +3.17% |
| ▲ Q4 FY2025 | Nov 26, 2025 | +38.9% | $0.82 | $0.92 | +12.40% |
| ▲ Q3 FY2025 | Aug 28, 2025 | +175.9% | $1.39 | $1.38 | -0.72% |
| ▲ Q2 FY2025 | May 22, 2025 | +30.3% | $1.37 | $1.41 | +2.92% |
| — Q2 FY2025 | Apr 2, 2025 | — | $1.42 | $1.50 | +5.63% |
| — Q4 FY2024 | Nov 14, 2024 | — | $2.99 | $3.10 | +3.68% |
| — Q3 FY2024 | Aug 28, 2024 | — | $3.55 | $3.22 | -9.30% |
Q1 FY2026+3.17%
Report Date
Mar 31, 2026
EPS Beat/Miss
-142.1%
Price Before
$0.47
Price After
$0.49
Q1 FY2026+3.17%
Report Date
Mar 31, 2026
EPS Beat/Miss
-56.9%
Price Before
$0.47
Price After
$0.49
Q4 FY2025+12.40%
Report Date
Nov 26, 2025
EPS Beat/Miss
+38.9%
Price Before
$0.82
Price After
$0.92
Q3 FY2025-0.72%
Report Date
Aug 28, 2025
EPS Beat/Miss
+175.9%
Price Before
$1.39
Price After
$1.38
Q2 FY2025+2.92%
Report Date
May 22, 2025
EPS Beat/Miss
+30.3%
Price Before
$1.37
Price After
$1.41
Q2 FY2025+5.63%
Report Date
Apr 2, 2025
EPS Beat/Miss
—
Price Before
$1.42
Price After
$1.50
Q4 FY2024+3.68%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$2.99
Price After
$3.10
Q3 FY2024-9.30%
Report Date
Aug 28, 2024
EPS Beat/Miss
—
Price Before
$3.55
Price After
$3.22
Avg Beat Reaction+4.87%
Avg Miss Reaction+3.17%
Beat Rate3 / 8 quarters
Largest Move+12.40% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GLMD ends December
Galmed Pharmaceuticals Ltd. (GLMD) most recently reported earnings on March 31, 2026 for Q1 FY2026, posting EPS of $-0.92 — missing the analyst consensus of $-0.38 by -142.1%. The next GLMD earnings date is expected around September 1, 2026.
Each quarter, investors track GLMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GLMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GLMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GLMD earnings · 5 questionsGalmed Pharmaceuticals Ltd.'s next earnings report is expected around September 1, 2026. GLMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GLMD historically reports after market close (AMC).
GLMD earnings datewhen is GLMD earningsGLMD next earnings datewhen does GLMD report earningsGLMD earnings calendar
▸ Source: FMP · Galmed Pharmaceuticals Ltd. SEC filings · US GAAP · Galmed Pharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026